

Professor Gert Ossenkoppele is appointed in 2003 as professor of Hematology at the VU University Medical Center in Amsterdam. Gert Ossenkoppele has authored over 400 publications in peer-reviewed journals and is invited speaker at many national and international scientific meetings. His research interests is mainly translational and include the (stemcell) biology of AML, leukemic stem cell target discovery, immunotherapy and measurable residual disease (MRD) detection using flow cytometry to inform treatment of AML. He is PI of national and international clinical trials in myeloid malignancies. He chairs the AML working party of HOVON (Dutch-Belgian Hematology Trial Group) and is appointed as vice-chair of the HOVON Executive Board. He is a lead participant of the AML Work package of the European LeukemiaNet(ELN) as well as a board member of the ELN foundation.. He is recently appointed as chair of the EHA Educational Committee). He chairs the AML Scientific working group of EHA. He is chair of the Global and EU steering committee of the AMLGlobalPortal an educational portal for hematologists. ( [www.amlglobalportal.com](http://www.amlglobalportal.com) ).